RadioGel^™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.

The IsoPet^® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.

In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet ^® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet ^® to University animal hospitals and private veterinary clinics.

INVESTOR CONTACT:

 
Vivos Inc.
Michael Korenko, Sc.D. – President & CEO

info@vivosinc.co

Safe Harbor Statement

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

IsoPet ^® for treating animals uses the same technology as RadioGel ^™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

Vivos Inc. (Trading symbol OTCQB: RDGL) is committed to providing shareholders with complete, up-to-the-minute information about the company. Our website is under construction. In the meantime on OTC Markets you'll find Press Releases, Financial Information, Board of Directors, Committee Composition, Governance Documents, and other corporate information.

Thank you for your past and continued support investing in Vivos Inc., and for supporting our mission of developing technologies that will improve human life.